Ted W. Johnson

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission

Smruthi Karthikeyan, Joshua I. Levy, Peter De Hoff et al. · Nature · 2022 · 520 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F

Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner et al. · New England Journal of Medicine · 2015 · 484 citations · Full text

Medicine, Oncology, Pharmacology +16

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 463 citations · Full text

Medicine, Oncology, Pharmacology +14

Using the Golden Triangle to optimize clearance and oral absorption

Ted W. Johnson, Klaus Dress, Martin P. Edwards · Bioorganic & Medicinal Chemistry Letters · 2009 · 382 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +14